Regenerative Therapy and Surgery: Not Either-Or

A lot of patients arrive here framing the decision as a binary: "I want to try regenerative therapy so I can avoid surgery." Sometimes that framing is right. Often it isn't. The honest version is that surgery and regenerative therapy are tools on the same shelf, and the question is which one fits this patient, this joint, at this stage.

This guide walks through how we think about that decision. It's longer than most patient-facing decision guides because the choice has real consequences (in money, time, and recovery), and the framework that produces good decisions is more nuanced than "cells first, surgery second."

The decision tree

For most orthopedic indications, the workup sorts patients into one of four categories:

Category 1: Conservative therapy is still appropriate. PT, weight management, activity modification, NSAIDs, sometimes a steroid injection. Some patients arrive at our clinic who genuinely haven't given conservative care a fair run. The right answer is to do that first, with reasonable timeframes and clear criteria for when to escalate.

Category 2: Regenerative therapy is the right next step. Moderate joint disease, intact joint structure, soft tissue or cartilage that has capacity to respond. This is where PRP, stem cell, and exosome protocols do their best work.

Category 3: Mixed approach. Regenerative therapy plus surgical consultation. Some cases benefit from both. A meniscal repair plus PRP, an ACL reconstruction with biologic augmentation, a rotator cuff repair with post-op regenerative support. The literature on combined approaches is growing fast.

Category 4: Surgery is the right answer. End-stage osteoarthritis with severe functional limitation, complete tendon tears, mechanical instability, or anatomic problems that cells can't solve. Cells don't fix a torn ACL. They don't realign a varus knee. They don't replace a hip joint that's already collapsed.

A clinic that funnels every patient into category 2 isn't doing the workup. A surgeon who funnels every patient into category 4 isn't either.

Where regenerative therapy adds the most value

The clearest win for regenerative protocols, in our practice and in the literature, is the "gap year" patient. Concretely: a 55-year-old with moderate knee osteoarthritis, still working, not yet a candidate for replacement (or wants to delay), who has failed PT and conservative care.

In this group:

A stem cell or exosome protocol can produce meaningful pain reduction and functional improvement for 12 to 24+ months.

That window often coincides with when the patient wants to stay active, maintain weight loss, recover from a major life event, or simply postpone surgery to a more convenient time.

When surgery eventually does happen, it happens at a point that fits the patient's life rather than at the height of a pain crisis.

The same logic applies to:

Moderate shoulder osteoarthritis or rotator cuff pathology before reverse total shoulder replacement becomes the right answer.

Moderate hip osteoarthritis in patients who want to delay replacement.

Lumbar facet and disc-mediated pain in patients who aren't yet candidates for spinal surgery.

A different kind of "gap" patient is the one who needs surgery but is medically optimizing first. Patient awaiting knee replacement who has six months of cardiac clearance and weight optimization ahead; we can sometimes meaningfully reduce pain during that bridge period.

A walkthrough by Kellgren-Lawrence grade (knee OA)

The Kellgren-Lawrence (KL) grading system for knee osteoarthritis is the standard radiographic classification. It's worth understanding because the right intervention shifts substantially across the grades.

KL grade 0. No radiographic evidence of OA. If you're symptomatic, the problem is something other than OA, and the workup should look for it.

KL grade I. Doubtful narrowing of joint space, possible osteophytic lipping. Symptoms are usually mild and intermittent. Conservative care first. If injection-level therapy is considered, PRP fits this stage; cellular therapy is overkill.

KL grade II. Definite osteophytes, possible joint space narrowing. PRP is the usual right answer for symptomatic patients who've failed conservative care. Cellular therapy may be appropriate for higher-demand patients (former athletes, those whose work demands intact knee function) but is often more than needed.

KL grade III. Moderate multiple osteophytes, definite joint space narrowing, some sclerosis, possible deformity. This is the cellular-therapy sweet spot. The cartilage damage is real, but the joint structure is still meaningfully intact. The published evidence for MSC therapy in this grade is the strongest in the regenerative literature.

KL grade IV. Large osteophytes, marked joint space narrowing, severe sclerosis, definite deformity. Surgical consultation is usually the right next step. Cells don't reverse bone-on-bone disease. We've declined patients in this category many times, and we'll continue to.

There are gray-zone patients in late KL III / early KL IV where the decision is genuinely close. Those are the patients where a thorough discussion of the trade-offs, the patient's surgical risk profile, and the patient's goals matters most.

The shoulder analogue

The shoulder uses different grading systems for different pathologies (Hamada for cuff-deficient arthropathy, Walch for glenoid morphology, Sugaya for cuff repair healing, etc.), and the decision logic differs by which structure is the problem.

Rotator cuff tendinopathy without tear. PRP first. Tendon responds to growth factor signaling. Sometimes shockwave priming first. Cellular therapy is rarely the right first answer for pure tendinopathy.

Rotator cuff partial-thickness tear under 50% thickness. PRP first, with a real shot at avoiding surgical repair. The published outcomes for PRP in this population are reasonable, and the alternative (early surgical repair of a partial tear) has its own complication and outcome profile.

Rotator cuff partial-thickness tear over 50% thickness, or chronic full-thickness tear of moderate size. Decision-point territory. Some patients are reasonable surgical candidates with biologic augmentation; others can defer surgery for years with conservative care plus regenerative support; others should proceed to repair sooner rather than later. The clinical and imaging picture decides.

Rotator cuff massive tear with retraction and atrophy. Surgical consultation. Often a reverse total shoulder arthroplasty is the right path. Cellular therapy at this point can produce symptomatic relief but won't reverse the structural problem.

Glenohumeral osteoarthritis, moderate. Cellular therapy can produce meaningful benefit, particularly for younger patients who aren't yet ready for arthroplasty. Image guidance is critical (the shoulder joint is harder to access than the knee).

Glenohumeral osteoarthritis, severe. Total or reverse total shoulder arthroplasty are typically the right answer, depending on cuff status.

Adhesive capsulitis (frozen shoulder). Different pathology, different treatment. Shockwave plus aggressive PT plus sometimes hydrodilatation or intra-articular steroid is more often the right answer than cellular therapy.

The hip analogue

The hip is deeper, harder to access, and harder to treat than the knee. The regenerative literature is smaller here, but the principles are similar.

Hip osteoarthritis, mild to moderate. Cellular therapy with ultrasound guidance, often paired with addressing concurrent hip flexor or gluteal contributions. PRP has a smaller evidence base in hip OA than in knee.

Hip osteoarthritis, severe. Total hip replacement. Hip replacement is one of the most successful procedures in orthopedic surgery, with high satisfaction rates and excellent functional outcomes. Cellular therapy is not a substitute for it.

Avascular necrosis (osteonecrosis) of the femoral head, early stage. A more interesting case. Cellular therapy has emerging support for delaying or avoiding hip replacement when the disease is caught early (Ficat stage I or II without collapse). The published data show some early signal of slowing or preventing progression, though the evidence base is smaller than for knee OA. We coordinate with orthopedic surgery on these cases.

Avascular necrosis with femoral head collapse. Surgical territory, usually total hip replacement. Cellular therapy at this point can't reverse the collapse.

Greater trochanteric pain syndrome and gluteal tendinopathy. PRP, sometimes paired with shockwave. Cellular therapy rarely the right first answer.

Hip labral tear. Mechanical problem. Surgical evaluation if symptomatic. PRP may have a role as a supplement, but the labral tear itself is a structural question.

The spine analogue

Spine is more complex than the appendicular joints, in part because the pain source is harder to pin down. Imaging findings often don't correlate with symptoms; "abnormal" findings exist in plenty of asymptomatic adults. The workup matters more here than almost anywhere else.

Lumbar facet-mediated pain. Diagnostic facet injection followed by therapeutic injection (often a PRP-into-facet protocol) for confirmed cases. Cellular therapy has emerging support but the evidence is smaller. Radiofrequency ablation remains a competitive option for confirmed facet pain.

Discogenic lumbar pain. A more nuanced case. Some patients are candidates for intradiscal regenerative protocols (PRP into the disc, exosomes, sometimes MSCs) when conservative care has failed and the clinical picture clearly points to the disc as the source. The evidence base is growing but mixed. We're careful with patient selection.

Lumbar radiculopathy. Often a mechanical problem (disc herniation compressing a nerve root). Conservative care first; epidural steroid injection if needed; surgical consultation if persistent. Cellular therapy is rarely the right answer in active radiculopathy, though some patients benefit from a regenerative adjunct after surgical decompression.

Cervical pain syndromes. Similar logic. Conservative care, targeted injections for confirmed pain generators, surgical consultation when indicated. Cellular therapy in the cervical spine has a smaller evidence base and we're more conservative about it.

Sacroiliac joint dysfunction. PRP into the SI joint has reasonable evidence. Cellular therapy is sometimes appropriate for more chronic cases.

Cauda equina or progressive neurological deficits. Spinal surgical emergencies; cells aren't on the menu.

Where surgery is usually the right answer first

Some pictures point to surgery directly:

Complete tendon ruptures. A full-thickness Achilles, a complete quad tendon rupture, a high-grade rotator cuff tear with retraction. Cells don't reconnect torn tissue.

Mechanical symptoms with loose bodies or displaced fragments. A locking knee with a bucket-handle meniscal tear, a hip with a loose body causing impingement.

Severe deformity. A varus or valgus knee with significant malalignment will not improve with cells; the mechanics are working against the biology.

End-stage joint disease. Bone-on-bone, severe sclerosis, large osteophytes, near-zero joint space. The hardware option exists for a reason.

Cauda equina or progressive neurological deficits. Spinal surgical emergencies; cells aren't on the menu.

Instability. Frank joint instability after ligament injury. The structural restoration usually has to come first.

Septic joint or active infection. Immediate surgical or medical attention. Regenerative therapy is contraindicated.

Malignancy in the joint or adjacent structures. Different workup entirely. Regenerative therapy is contraindicated.

If your case fits one of these and a regenerative clinic still pitches you a stem cell protocol, that's malpractice with marketing on top.

Where surgery and regenerative therapy combine

A growing literature supports adjunctive biologic use in specific surgical contexts:

Cartilage repair surgery. Microfracture, OATS (osteochondral autograft transplantation), MACI (matrix-induced autologous chondrocyte implantation). PRP and BMAC augmentation have evidence of improving graft integration and outcomes.

Rotator cuff repair. Biologic augmentation at the repair site has emerging evidence of improving healing rates, particularly in larger tears and older patients where the native repair biology is compromised.

ACL reconstruction. PRP augmentation has reasonable evidence for graft maturation; stem cell adjuncts have a smaller but growing literature.

Spinal fusion. Cellular augmentation of fusion constructs (often BMAC or DBM-cell composites) has been used for years with reasonable outcomes data.

Post-operative recovery support. For some procedures, a regenerative protocol in the recovery phase (typically 6 to 12 weeks post-op, once acute healing has progressed) can support tissue recovery.

For these cases, we work alongside the orthopedic team rather than against them. The right surgeon, the right biologic, sequenced correctly.

Pre-op biologic augmentation

A different use case: regenerative therapy before a planned surgery, to optimize tissue health going in.

The logic: patients with severe osteoarthritis often have multiple soft tissue contributors to their disability (capsular thickening, peri-articular tendinopathy, weakened periarticular muscles). Addressing these before surgery may improve the surgical recovery and the long-term result.

We do this selectively, in coordination with the surgeon, when the surgeon agrees it's a reasonable approach. It's not standard, the evidence base is limited, and we don't recommend it for every patient.

Post-op rehabilitation with biologics

A more established use case. Once acute surgical healing has progressed (typically 6 to 12 weeks post-op), some patients benefit from regenerative support to optimize the recovery trajectory. Examples:

A patient 8 weeks post-rotator cuff repair with persistent stiffness and slow tendon-to-bone integration. A targeted PRP injection at the repair site, in coordination with the surgeon, may support continued recovery.

A patient 12 weeks post-microfracture with developing chondrogenic tissue that could benefit from cellular augmentation.

A patient 6 months post-ACL reconstruction with a maturing graft that's still stiff or symptomatic. Adjunctive biologic care may help.

The coordination with the surgical team matters. We don't run post-op protocols behind the surgeon's back. We talk to them, share notes, and time interventions appropriately.

How we coordinate with surgeons

Patients often arrive at Apex either from a surgeon (who has recommended trying conservative therapy first or wants biologic augmentation) or considering whether to go see a surgeon next.

When we recommend a surgical consult, we name names. We have a working relationship with several orthopedic surgeons in the metroplex who practice evidence-based medicine and aren't dismissive of biologic options. When a patient comes to us from a surgeon, we close the loop with that surgeon: a written summary of the protocol, expected timelines, and how to interpret what happens next.

If your surgeon is open-minded, this works smoothly. If they aren't, we'll still see you, and we'll still tell you honestly when we think you should circle back to them.

A common pattern: a patient has been told by a surgeon "you're a year away from replacement." That year is often when regenerative therapy can produce its biggest patient-experience impact. The patient still ends up having the surgery eventually, but they're more comfortable in the interim, and the timing of the surgery becomes a decision rather than a crisis.

How to evaluate a surgical recommendation

A few questions worth asking any orthopedic surgeon recommending a procedure:

What conservative or non-surgical options remain that I haven't tried?

What's the expected outcome of the surgery (function, pain, return to activity)?

What's the expected recovery timeline?

What are the specific risks for me given my health context?

How many of these procedures do you do per year?

What's your re-operation rate?

What happens if I wait six months?

Good surgeons answer these directly. Less-good ones sometimes don't. The answers help you calibrate.

A 10-year horizon framework

A useful exercise during the decision: think in 10-year time horizons instead of next-month time horizons.

Patient A is 55 with moderate knee OA. Conservative care has stopped working. Options:

Path 1: Continue conservative care, accepting gradual deterioration. Probably leads to surgery at age 60 to 62.

Path 2: Cellular therapy now, with maintenance dosing. Possibly delays surgery to 63 to 67, possibly avoids it for longer.

Path 3: Surgery now. Recovery period, probable good outcome, decision-driven timing.

Each path has trade-offs in cost, time, recovery, and life impact. The "right" path depends on the patient's specific values. A 55-year-old who's a professional musician and travels constantly may have a different calculus than a 55-year-old who's about to retire and wants to garden.

The point of the framework is to make the decision deliberate. Not "should I try cells before surgery?" but "given my life over the next 10 years, which sequence of interventions gives me the best probable result?"

A few illustrative cases

Case A. A 51-year-old runner with moderate medial-compartment knee OA, intact menisci, mild varus alignment, failed PT and one steroid injection. We treated with a stem cell and exosome protocol and a sequenced shockwave course. She's back to recreational running at 9 months, returning for re-evaluation at 18 months.

Case B. A 68-year-old with grade-IV osteoarthritis, severe varus deformity, and a meniscal root tear. We declined a regenerative protocol and referred to an orthopedic surgeon. She had a total knee replacement and is doing well at 6 months post-op.

Case C. A 42-year-old with a partial supraspinatus tear, capable of repair but not yet symptomatic enough to require it. We treated with a PRP protocol with image guidance. He's pain-free at 14 months. We've told him to call us back if symptoms recur and to consider surgical consult if they do.

Case D. A 58-year-old, 6 weeks post-partial meniscectomy and microfracture, with persistent pain and the surgeon's blessing for a regenerative augment. We treated with a cellular protocol at the appropriate timepoint and coordinated with the orthopedic team. She returned to her baseline activity by month 5.

Case E. A 63-year-old recommended for total hip replacement by his surgeon, with a 6-month wait for the surgery date. We treated with a stem cell hip protocol as bridge therapy. His pain improved enough that he was substantially more comfortable through the wait period, and the surgery went forward as planned at the right time.

The pattern is the same in all of them: imaging, exam, and goals decide the protocol. Regenerative medicine, surgery, or a combination, in whichever order the case calls for.

The honest summary

Regenerative therapy is not an alternative to surgery. It's a different tool that's right for some cases and wrong for others, and the workup is what decides.

If you're trying to figure out whether you belong with us, with a surgeon, or with both in sequence, request a consultation or call (972) 768-2328. We'll tell you the truth even when the truth points to a surgeon.

A short note from Dr. Abdullah

I send a meaningful number of patients to orthopedic surgeons every year. It's not a failure mode. It's part of the practice. Patients who get a clean surgical answer when surgery is the right answer end up healthier and happier than patients who chase regenerative protocols for a problem cells can't solve. Doing right by patients sometimes means sending them somewhere else. The relationships I have with local surgeons reflect that we both respect each other's tools and limits. That's the kind of practice this should be.